0001193125-26-209324
SEC filingAcadia Healthcare Company, Inc. held its 2026 annual stockholder meeting, electing three Class III directors, approving the second amendment to its Incentive Compensation Plan, approving executive compensation on an advisory basis, and ratifying Ernst & Young LLP as independent auditors.
The annual meeting results reflect strong shareholder support for the Company's board and governance proposals. All three Class III director nominees received overwhelming approval with over 73 million 'for' votes each, serving until the 2029 annual meeting, ensuring board continuity in overseeing the Company's behavioral healthcare operations. The Incentive Compensation Plan amendment passed decisively, likely enabling updated equity incentives to align management with shareholder interests. Executive compensation received advisory approval despite 20 million against votes, signaling some investor scrutiny but overall acceptance as disclosed in the March 25, 2026 proxy statement. Auditor ratification was nearly unanimous, affirming confidence in Ernst & Young LLP for the 2026 fiscal year audit.